Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease

Acta Neurologica Scandinavica

Volumn 114, Issue 2, 2006, Pages 124-132

  Toth, C ^a   McDonald, D ^b   Oger, J ^c   Brownell, K ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Diabetes; Myasthenia gravis; Thyroid disease

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; PREDNISONE;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; EYE DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PATHOLOGY; PREVALENCE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; THYMOMA; THYMUS HYPERPLASIA; THYROID DISEASE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ALBERTA; AUTOANTIBODIES; CAUSALITY; CHILD; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PREVALENCE; PROSPECTIVE STUDIES; RECEPTORS, CHOLINERGIC; RETROSPECTIVE STUDIES; RISK; SEX DISTRIBUTION; THYMOMA; THYMUS NEOPLASMS; THYROID DISEASES;

EID: 33745863923     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2006.00649.x     Document Type: Article

References (31)

1. VINCENT A, PALACE J, HILTON-JONES D. Myasthenia gravis. Lancet 2001;357:2122-8.
2. KAMINSKI HJ. Myasthenia gravis and related disorders. New Jersey: Humana Press, 2003.
3. ALMON RR, ANDREW CG, APPEL SH. Serum globulin in myasthenia gravis: inhibition of a-bungarotoxin binding to acetylcholine receptors. Science 1974;186:55-7.
4. LINDSTROM J. Immunobiology of myasthenia gravis, experimental autoimmune myasthenia gravis, and Lambert-Eaton syndrome. Ann Rev Immunol 1985;3:109-31.
5. HOCH W, MCCONVILLE J, HELMS S, NEWSOM-DAVIS J, MELMS A, VINCENT A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-8.
6. SCUDERI F, MARINO M, COLONNA L et al. Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab Invest 2002;82:1139-46.
7. AGIUS M, RICHMAN D, FAIRCLOUGH R, AARLI JA, GILHUS NE, ROMI F. Three forms of immune myasthenia. Ann NY Acad Sci 2003;998:453-6.
8. OH SJ. Electrophysiological characteristics in seronegative myasthenia gravis. Ann N Y Acad Sci 1993;681:584-7.
9. KEESEY JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004;29:484-505.
10. VINCENT A, BOWEN J, NEWSOM-DAVIS J, MCCONVILLE J. Sero-negative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol 2003;2:99-106.
11. ROMI F, GILHUS NE, AARLI JA. Myasthenia gravis: clinical, immunological, and therapeutic advances. Acta Neurol Scand 2005;111:134-41.
12. AARLI JA, ROMI F, SKEIE OG, GILHUS NE. Myasthenia gravis in individuals over age forty. Ann NY Acad Sci 2003;998:424-31.
13. THORLACIUS S, AARLI JA, RIISE T, MATRE R, JOHNSEN HJ. Associated disorders in myasthenia gravis: autoimmune diseases and their relation to thymectomy. Acta Neurol Scand 1989;80:290-5.
14. OGER J, KAUFMAN R, BERRY K. Acetylcholine receptor antibodies in myasthenia gravis: use of a qualitative assay for diagnostic purposes. CJNS 1987;14:297-302.
15. JARETZKI A 3RD, BAROHN RJ, ERNSTO RM, KAMINSKI HJ, KEESEY JC, PENN AS, SANDERS DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
16. OSSERMAN KE. Clinical aspects. In: Osserman KE, ed. Myasthenia gravis. New York, NY: Grune & Stratton, 1958;79-80.
17. AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve 2001;24:1239-47.
18. LINDSTROM JM, SEYBOLD ME, LENNON VA, WHITTINGHAM S, DUANE DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-9.
19. VINCENT A, MCCONVILLE J, FARRUGIA ME et al. Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci 2003;998:324-35.
20. PLESTED CP, TANG T, SPREADBURY I, LITTLETON ET, KISHORE U, VINCENT A. AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology 2002;59:1682-8.
21. SELCEN D, FUKUDA T, SHEN XM, ENGEL AG. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004;62:1945-50.
22. LINDSTROM JM, SEYBOLD ME, LENNON VA, WHITTINGHAM S, DUANE DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-9.
23. FERRERO B, AIMO G, PAGNI R, BERGAMASCO B, BONGIOANNI MR, BERGAMINI L, DURELLI L. Modified and improved antiacetylcholine receptor (AChR) antibody assay: comparison of analytical and clinical performance with conventional anti-AChR antibody assay. Clin Chem 1997;43:824-831.
24. OH SJ, KIM DE, KURUOGLU R, BRADLEY RJ, DWYER D. Diagnostic sensitivity of the laboratory tests in myasthenia gravis. Muscle Nerve 1992;15:720-4.
25. ROUSEEV R, ASHBY P, BASINSKI A, SHARPE JA. Single fiber EMG in the frontalis muscle in ocular myasthenia: specificity and sensitivity. Muscle Nerve 1992;15:399-403.
26. HOWARD JF, SANDERS DB, MASSEY JM. The electrodiagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Neurol Clin 1994;12:305-30.
27. GIRAUD M, BEAURAIN G, YAMAMOTO AM, EYMARD B, TRANCHANT C, GAJDOS P, GARCHON HJ. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology 2001;57:1555-60.
28. KRAEMER MH, DONADI EA, TAMBASCIA MA, MAGNA LA, PRIGENZI LS. Relationship between HLA antigens and infectious agents in contributing towards the development of Graves' disease. Immunol Invest 1998;27:17-29.
29. BARKER JM, BARRIGA KJ, YU L et al. Prediction of autoantibody positivity and progression to type 1 diabetes: diabetes autoimmunity study in the young (DAISY). J Clin Endocrinol Metab 2004;89:3896-902.
30. YOSHIKAWA H, LENNON VA. Acetylcholine receptor autoantibody secretion by thymocytes: relationship to myasthenia gravis. Neurology 1997;49:562-7.
31. KARNI A, ZISMAN E, KATZ-LEVY Y et al. Reactivity of T cells from seronegative patients with myasthenia gravis to T cell epitopes of the human acetylcholine receptor. Neurology 1997;48:1638-42.